Biopharma Credit PLC

Overview

Biopharma Credit PLC is a British investment trust focusing on debt investments secured by life sciences product royalties. The company primarily invests in interest-bearing debt assets, with debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products. The company is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index. The company is managed by Pharmakon Advisors, LP, which has committed over $10 billion across 62 transactions supporting companies in the life sciences sector. The chairman of the company is Harry Hyman, who is also the founder and Chair of Primary Health Properties PLC, a FTSE 250 Real Estate Investment Trust specializing in the ownership of property leased on a long-term basis to healthcare providers. The company has a diversified portfolio of loans and other instruments backed by royalties or other cash flows derived from sales of approved life sciences products. The company's primary objective is to generate predictable income for shareholders over the long term, targeting an annual dividend yield of 7% and a net total return on NAV of 8 to 9% per annum in the medium term. The company has a track record of paying a dividend of at least 1.75 cents per share in every quarter since 30 June 2018. The company's investment approach is comprehensive and flexible, specializing in providing non-dilutive debt capital to a broad spectrum of life sciences companies, from emerging growth innovators to established commercial-stage companies. The company's team is composed of seasoned professionals with deep expertise spanning biotechnology, pharmaceuticals, medical technology, and finance, enabling the delivery of customized financing solutions for companies while generating competitive risk-adjusted returns for investors.

Investment Focus

• Investments must be secured by royalties or other cash flows derived from the sales of approved life sciences products.

Portfolio Companies